Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult males and/or females (of Non Child-bearing potential), 18 to 55 years of age~* Body mass index (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive).~* Medically healthy with clinically insignificant screening results~* Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to Day 1.~* Sexually abstinent or use acceptable methods of birth control~Exclusion Criteria:~* History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.~* History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.~* Documented hypersensitivity reaction or anaphylaxis to any medication.~* Use of any over-the-counter (OTC) medication, including herbal products and vitamins, within the 7 days prior to Day 1. Up to 2 grams per day of acetaminophen is allowed for acute events at the discretion of the PI.~* Plasma donation within 7 days prior to Day 1.~* Subjects who have any abnormalities on laboratory values at screening or check-in (Day -1).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Ascending Single and Multiple dose of RPX7009 (Type: EXPERIMENTAL): Ascending Single and Multiple dose of RPX7009
- Normal Saline (Type: PLACEBO_COMPARATOR): Ascending Single and multiple dose of normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).